These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 18946341

  • 1. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.
    van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, Lohmus A, Sommerer C, Hartmann A, Le Meur Y, Oellerich M, Holt DW, Tönshoff B, Keown P, Campbell S, Mamelok RD.
    Transplantation; 2008 Oct 27; 86(8):1043-51. PubMed ID: 18946341
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients.
    Prémaud A, Rousseau A, Le Meur Y, Venisse N, Loichot C, Turcant A, Hoizey G, Compagnon P, Hary L, Debruyne D, Saivin S, Jacqz-Aigrain E, Marquet P.
    Pharmacol Res; 2010 Feb 27; 61(2):167-74. PubMed ID: 19800973
    [Abstract] [Full Text] [Related]

  • 4. Short-term therapeutic drug monitoring of mycophenolic acid reduces infection: a prospective, single-center cohort study in Chinese living-related kidney transplantation.
    Fu L, Huang Z, Song T, He S, Zeng D, Rao Z, Xie L, Song Y, Wang L, Lin T.
    Transpl Infect Dis; 2014 Oct 27; 16(5):760-6. PubMed ID: 25092411
    [Abstract] [Full Text] [Related]

  • 5. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.
    Gourishankar S, Houde I, Keown PA, Landsberg D, Cardella CJ, Barama AA, Dandavino R, Shoker A, Pirc L, Wrobel MM, Kiberd BA.
    Clin J Am Soc Nephrol; 2010 Jul 27; 5(7):1282-9. PubMed ID: 20498245
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
    Kiberd BA, Lawen J, Daley C.
    Ther Drug Monit; 2012 Dec 27; 34(6):736-8. PubMed ID: 23007746
    [Abstract] [Full Text] [Related]

  • 8. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, van Gelder T, Cattaneo D.
    Transplant Rev (Orlando); 2011 Apr 27; 25(2):47-57. PubMed ID: 21190834
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.
    Cooper M, Deering KL, Slakey DP, Harshaw Q, Arcona S, McCann EL, Rasetto FA, Florman SS.
    Transplantation; 2009 Aug 27; 88(4):514-20. PubMed ID: 19696634
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation.
    van Gelder T, Silva HT, de Fijter H, Budde K, Kuypers D, Mamelok RD, Armstrong VW, Oellerich M.
    Ther Drug Monit; 2011 Apr 27; 33(2):155-64. PubMed ID: 21383657
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.
    Barau C, Barrail-Tran A, Hemerziu B, Habes D, Taburet AM, Debray D, Furlan V.
    Liver Transpl; 2011 Oct 27; 17(10):1152-8. PubMed ID: 21695772
    [Abstract] [Full Text] [Related]

  • 16. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, Tueros L, Hanson L, Rosen A, Ruiz P, Miller J.
    Transplantation; 2008 Jul 15; 86(1):67-74. PubMed ID: 18622280
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
    Kuypers DR, de Jonge H, Naesens M, de Loor H, Halewijck E, Dekens M, Vanrenterghem Y.
    Clin Ther; 2008 Apr 15; 30(4):673-83. PubMed ID: 18498916
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.
    Pape L, Ehrich JH, Offner G.
    Clin Transplant; 2004 Oct 15; 18(5):576-9. PubMed ID: 15344963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.